OBJECTIVE
When Congress established average sales price (ASP) as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and limiting potentially excessive Medicare payment amounts. Section 1847A(d)(1)-(3) of the Social Security Act mandates that OIG compare ASPs with average manufacturer prices (AMPs) and widely available market prices (WAMPs) (if any). If OIG finds that the ASP for a drug exceeds the AMP by 5 percent in the two previous quarters or three of the previous four quarters, the Secretary of Health and Human Services may substitute the reimbursement amount with a lower calculated rate.
There are 4 projects in this series.
ACTIVE PROJECTS IN THIS SERIES (4)
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2026
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2026
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2026
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2027
TIMELINE
-
November 16, 2026Series Number SRS-E-27-001 Assigned
-
November 16, 2026Projects Announced
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2026 - OEI-03-27-00010
-
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2026 - OEI-03-27-00020
-
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2026 - OEI-03-27-00030
-
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2027 - OEI-03-27-00040
-
Today4 Evaluations In-Progress
-
Est FY2027Estimated Fiscal Year for Series Completion